drugsinfo

سلام

دوستان سفارشات دارویی خود را برای ایران (از دبی) به آدرس زیر ایمیل کنید:

aslamah.khanian@gmail.com

با تشکر

آیا می دانستید؟

داروها هنگامیکه وارد بدن می شوند معمولا با ماکرومولکولهای سلولی (target cells) کنش و واکنش انجام میدهدند. این ماکرومولکولها پروتیینهایی هستند که در حکم کانالهای یونی یا آنزیم یا مولکول حمل کننده (carriers) یا رسپتور عمل می کنند.

(ادامه دارد...)

ISSUE: Multi-Mex Distributor, Inc., recalled dietary supplements that may be labeled as antibiotic drugs. The recall was initiated after an FDA inspection revealed the product packaging mimics antibiotics readily available in Mexico and possibly familiar to Hispanic consumers
The products were distributed in the following states: Georgia, Tennessee, California, Illinois, Texas, North Carolina, South Carolina, Colorado, and Indianapolis, to the retail store and distributors

ISSUE: FDA laboratory analysis confirmed that "Slim Xtreme Herbal Slimming Capsule" contains sibutramine. Sibutramine is a controlled substance that was withdrawn from the U.S. market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, and stroke. This product may also interact in life threatening ways with other medications a consumer may be taking

FDA, FTC act to remove fraudulent STD products from the market.This is a reprint of the FDA alert

The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) today announced a joint effort to remove products from the market that make unproven claims to treat, cure, and prevent sexually transmitted diseases (STDs). Among the products targeted in today"s action are Medavir, Herpaflor, Viruxo, C-Cure, and Never An Outbreak
 
The agencies issued multiple letters to companies warning that their products violate federal law. These products, sold online and in retail outlets, have not been evaluated by the FDA for safety and effectiveness. The joint action is the first step in keeping these unproven items from being sold to the public and preventing consumers from being misled
 
The companies that received the warning letters claim that their products treat a range of STDs, including herpes, chlamydia, genital warts, HIV, and AIDS. While some of the companies market these products as dietary supplements, these products are all drug products under the Federal Food, Drug, and Cosmetic Act (FD&C Act), as they are offered for the treatment of disease.  These drug products, which are offered for the treatment of STDs, may not be introduced into interstate commerce without an FDA-approved new drug application (NDA)
 
"These products are dangerous because they are targeted to patients with serious conditions, where treatment options proven to be safe and effective are available," said Deborah M. Autor, director of the Office of Compliance in FDA"s Center for Drug Evaluation and Research. "Consumers who buy these products may not seek the medical attention they need and could spread infections to sexual partners"
 
Further, under the Federal Trade Commission Act it is illegal to make such unsubstantiated treatment claims
 
"These companies are on notice that advertising health benefits that are not supported by rigorous scientific evidence violates the FTC Act," said David Vladeck, director of the FTC"s Bureau of Consumer Protection. "They also should know that health scams that endanger public health will not be tolerated"
 
Consumers should be aware that there are no over-the-counter or online drugs or dietary supplements available to treat or prevent STDs. Appropriate treatment of STDs can only occur under the supervision of a health care professional. There are many FDA-approved medications available for treating these conditions, but they do require a preion
Our Warning Letters give these firms time to voluntarily comply with the law," said Dara Corrigan, the FDA"s associate commissioner for regulatory affairs. "The FDA will continue to take aggressive enforcement action against firms that market false treatments or cures that may lead to significant public health consequences"